Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as part of its strategic effort to accelerate and expand its proprietary radiopharmaceutical program. Defence has been collaborating with CNL on th
Biotechnologies, Pharmaceutique, Santé
2026-01-28 8:40 AM EST | Defence Therapeutics Inc.
Hear At Last Holdings Inc (HRAL) and GG&C Collaborate to Present New Housing Model to Jamaican Government
Miami, Florida--(Newsfile Corp. - January 28, 2026) - Hear At Last (OTCID: HRAL) on January 27/26 in collaboration with GG&C, is proud to announce the successful delivery of a comprehensive housing model for presentation to the Jamaican Government. This innovative model is designed to provide a framework for addressing the nation's housing needs and will enable key decision-makers to determine the best path forward for future housing development initiatives. The housing model presen
Produits ménagers / de consommation / cosmétiques, Santé
2026-01-28 8:00 AM EST | Hear AtLast Holdings, Inc
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides a corporate update and announces the intention to complete a small non-brokered private placement fina
2026-01-28 8:00 AM EST | Izotropic Corporation
Scryb Reports Fiscal 2025 Results; Strengthened Balance Sheet and Significant Cybeats Exposure
Toronto, Ontario--(Newsfile Corp. - January 28, 2026) - Scryb Inc. (CSE: SCYB) ("Scryb'' or the "Company") announces that it has filed its audited consolidated financial statements and Management's Discussion and Analysis for the fiscal year ended September 30, 2025 ("FY2025"). The filings are available on SEDAR+. Fiscal 2025 marked a transformative year for Scryb, highlighted by a materially strengthened balance sheet, significantly reduced operating costs, and a
Biotechnologies, Soins de santé et hôpitaux, Santé
2026-01-28 7:03 AM EST | Scryb Inc.
Invitation to Cosmo's Full Year 2025 Financial Results Webcast on 9 March 2026
Dublin, Ireland--(Newsfile Corp. - January 28, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2025 results on Monday, 9 March 2026 at 7:00 am CET. Live conference call and audio webcast presentation: Cosmo invites investors, financial analysts and business/life sciences journalists to a live webcast presentation which will follow on the same da
Soins de santé et hôpitaux, Santé
2026-01-28 1:24 AM EST | Cosmo Pharmaceuticals N.V.
Neural's Portfolio Company Hanf.com Announces Sales Start of Ritual Herbs Nicotine and Tobacco Free Products
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company"), an ethnobotanical drug discovery company focused on developing therapeutic solutions for mental health conditions related to substance use disorders, together with its portfolio company CWE European Holdings Inc. ("CWE"), operating as Hanf.com, one of Germany's leading CB
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-01-27 10:00 AM EST | Neural Therapeutics Inc.
Beckett's CEO Issues Shareholder Letter and The Company Announces Board Change
Ontario and Los Angeles, California--(Newsfile Corp. - January 27, 2026) - Beckett's Inc. (CSE: BKTS), a fast-growing non-alcoholic beverage brand shaking up the NA category, announces that Beckett's Chief Executive Officer, Larry Weintraub has issued a shareholder letter providing a recap on 2025 and an outlook for 2026. The Company also announces a change to its Board. Shareholder Letter from Larry Weintraub: Beckett's 2025 Recap and 2026 Outlook Dear Shar
Aliments / boissons, Cannabis, Santé
2026-01-27 7:30 AM EST | Becketts Inc.
Predictmedix AI Rebrands as QScreen AI Inc., (QAI) Harnessing Quantum-AI Synergy for Health Screening
Toronto, Ontario--(Newsfile Corp. - January 27, 2026) - QScreen AI Inc. (CSE: QAI) (OTC Pink: PMEDF) (FSE: 3QP0) (formerly Predictmedix AI Inc.), a pioneering leader in artificial intelligence enabled health and safety technology, is pleased to announce that, further to its news releases of January 12, 2026, the Company has completed its name change to QScreen AI Inc. (the "Name Change"). As a result of the Name Change the Company's common shares (the "Common Shares") are expe
2026-01-27 7:01 AM EST | QScreen AI Inc.
Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered mont
Soins de santé et hôpitaux, Santé
2026-01-26 10:00 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
Aleen Inc. Personal Account: Streamlined Navigation for Wellness Information
Toronto, Ontario--(Newsfile Corp. - January 26, 2026) - Aleen Inc. (CSE: ALEN.U), a digital wellness company, announces the rollout of enhanced navigation features within the Personal Account, its user-facing service for managing wellness information. The improvements focus on simplifying how users browse, locate, and interact with their wellness documents. By offering more intuitive menus, faster access paths, and clearer categorization, the updates aim to make personal w
2026-01-26 8:00 AM EST | Aleen Inc.
Cheelcare Announces Medicare and Medicaid Services Reimbursement Approval for Companion Power Assist Device, Expanding U.S. Market Access
Investment Highlights: U.S. Medicare and Medicaid reimbursement eligibility achieved: The Company has received Pricing, Data Analysis, and Coding ("PDAC") verification, enabling U.S. Medicare and Medicaid reimbursement for its Companion power assist device. Companion is a best-in-class, front-mounted add-on for manual wheelchairs that provides motorized assistance, helping users enable a higher quality of life.
2026-01-26 7:30 AM EST | Cheelcare Inc.
Optimi Health Completes First 2026 Production of MDMA and Psilocybin Capsules
Vancouver, British Columbia--(Newsfile Corp. - January 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical psychedelic drug products, today reported that it has completed a production cycle for its MDMA and psilocybin capsules intended for supply into Australia under the Authorised Prescriber Scheme. The completed batch consists of 1,000 MDMA capsules in a 60 mg dosage form and 1,000 n
Biotechnologies, Pharmaceutique, Santé, Psychédéliques
2026-01-26 7:00 AM EST | Optimi Health Corp.
TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Highlights Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature Designed for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors, and temperature- and light-sensitive glucose test strips Expanded portfolio to pursue larger
Technologies, Biotechnologies, Pharmaceutique, Santé
2026-01-23 4:05 PM EST | TempraMed Technologies Ltd.
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private placement of units (the "Units") of the Company (the "Offering"), including the full exercise of the over-allotment option. Canac
Biotechnologies, Cannabis, Santé, Producteurs de cannabis
2026-01-23 9:16 AM EST | Cardiol Therapeutics Inc.
Akanda Announces Closing of $7.0 Million Convertible Note Offering
Toronto, Ontario--(Newsfile Corp. - January 23, 2026) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company") today announced the closing of its previously announced transaction with institutional investors for the purchase and sale of 12 month, convertible promissory notes for an aggregate purchase price of $7.0 million, in a private placement transaction. The Company shall use the proceeds from the sale of the notes for (i) marketing purposes of up to $2.3 million, (ii) workin
Cannabis, Santé, Cultivateurs de cannabis, Producteurs de cannabis
2026-01-23 8:00 AM EST | Akanda Corp
DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™
2026-01-22 5:00 PM EST | DiagnosTear Technologies Inc.
FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the "Agreement") dated January 20, 2026 with Aquaox LLC ("Aquaox"), a U.S. based manufacturer of environmentally
Technologies, Soins de santé et hôpitaux, Santé
2026-01-22 5:00 PM EST | FendX Technologies Inc.
Safe Supply Streaming Co Ltd. Releases Strategic Corporate Update as Commercial Traction, Government Engagement, and Platform Expansion Accelerate
Toronto, Ontario--(Newsfile Corp. - January 22, 2026) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (OTCQB: SSPLF) (FSE: QM4) ("Safe Supply" or the "Company"), a pioneer in health, safety and rapid response technologies, today provided a comprehensive corporate update as the Company enters a new phase of growth marked by commercial execution, government engagement, and strategic brand evolution. Over the past several months, Safe Supply has methodically transitioned f
2026-01-22 7:07 AM EST | Safe Supply Streaming Co Ltd.
Apolo V Acquisition Corp. Enters into Definitive Agreement with Telyrx, Inc.
Toronto, Ontario--(Newsfile Corp. - January 21, 2026) - Apolo V Acquisition Corp. (TSXV: AFV.P) ("Apolo V" or the "Company") and TelyRx, Inc. ("TelyRx"), a vertically integrated technology enabled healthcare and pharmacy services company, are pleased to announce they have entered into a business combination agreement dated January 19, 2026 (the "Business Combination Agreement"), among others, to complete a go-public transaction for TelyRx (the "Propose
Soins de santé et hôpitaux, Santé
2026-01-21 4:42 PM EST | TelyRx